Global Biosimilar Drug Market Report and Forecast to 2021
Biosimilar Drug Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and comprehensive research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom,Japan, South Korea and China).
In this report, the global Biosimilar Drug market is valued at USD XX million in 2017 and is projected to reach USD XX million by the end of 2021, growing at a CAGR of XX% during the period 2017 to 2021.
The report firstly introduced the Biosimilar Drug basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world's main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.
The major players profiled in this report include:
Hengrui Medicine
Hisun Pharm
MSD
Pfizer
Novartis
Boehringer
The end users/applications and product categories analysis:
On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-
mAbs (Monoclonal Antibodies)
FC-Fusion Proteins
EPO (Erythropoietin)
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Biosimilar Drug for each application, including
Oncology
Diabetes
Rheumatoid arthritis
In this report, the global Biosimilar Drug market is valued at USD XX million in 2017 and is projected to reach USD XX million by the end of 2021, growing at a CAGR of XX% during the period 2017 to 2021.
The report firstly introduced the Biosimilar Drug basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world's main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.
The major players profiled in this report include:
Hengrui Medicine
Hisun Pharm
MSD
Pfizer
Novartis
Boehringer
The end users/applications and product categories analysis:
On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-
mAbs (Monoclonal Antibodies)
FC-Fusion Proteins
EPO (Erythropoietin)
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Biosimilar Drug for each application, including
Oncology
Diabetes
Rheumatoid arthritis
PART I BIOSIMILAR DRUG INDUSTRY OVERVIEW
CHAPTER ONE BIOSIMILAR DRUG INDUSTRY OVERVIEW
1.1 Biosimilar Drug Definition
1.2 Biosimilar Drug Classification Analysis
mAbs (Monoclonal Antibodies)
FC-Fusion Proteins
EPO (Erythropoietin)
1.2.1 Biosimilar Drug Main Classification Analysis
1.2.2 Biosimilar Drug Main Classification Share Analysis
1.3 Biosimilar Drug Application Analysis
Oncology
Diabetes
Rheumatoid arthritis
1.3.1 Biosimilar Drug Main Application Analysis
1.3.2 Biosimilar Drug Main Application Share Analysis
1.4 Biosimilar Drug Industry Chain Structure Analysis
1.5 Biosimilar Drug Industry Development Overview
1.5.1 Biosimilar Drug Product History Development Overview
1.5.1 Biosimilar Drug Product Market Development Overview
1.6 Biosimilar Drug Global Market Comparison Analysis
1.6.1 Biosimilar Drug Global Import Market Analysis
1.6.2 Biosimilar Drug Global Export Market Analysis
1.6.3 Biosimilar Drug Global Main Region Market Analysis
1.6.4 Biosimilar Drug Global Market Comparison Analysis
1.6.5 Biosimilar Drug Global Market Development Trend Analysis
CHAPTER TWO BIOSIMILAR DRUG UP AND DOWN STREAM INDUSTRY ANALYSIS
2.1 Upstream Raw Materials Analysis
2.1.1 Upstream Raw Materials Price Analysis
2.1.2 Upstream Raw Materials Market Analysis
2.1.3 Upstream Raw Materials Market Trend
2.2 Down Stream Market Analysis
2.1.1 Down Stream Market Analysis
2.2.2 Down Stream Demand Analysis
2.2.3 Down Stream Market Trend Analysis
PART II ASIA BIOSIMILAR DRUG INDUSTRY (THE REPORT COMPANY INCLUDING THE BELOW LISTED BUT NOT ALL)
CHAPTER THREE ASIA BIOSIMILAR DRUG MARKET ANALYSIS
3.1 Asia Biosimilar Drug Product Development History
3.2 Asia Biosimilar Drug Competitive Landscape Analysis
3.3 Asia Biosimilar Drug Market Development Trend
CHAPTER FOUR 2012-2017 ASIA BIOSIMILAR DRUG PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
4.1 2012-2017 Biosimilar Drug Capacity Production Overview
4.2 2012-2017 Biosimilar Drug Production Market Share Analysis
4.3 2012-2017 Biosimilar Drug Demand Overview
4.4 2012-2017 Biosimilar Drug Supply Demand and Shortage Analysis
4.5 2012-2017 Biosimilar Drug Import Export Consumption Analysis
4.6 2012-2017 Biosimilar Drug Cost Price Production Value Profit Analysis
CHAPTER FIVE ASIA BIOSIMILAR DRUG KEY MANUFACTURERS ANALYSIS
5.1 Hengrui Medicine
5.1.1 Company Profile
5.1.2 Product Picture and Specification
5.1.3 Product Application Analysis
5.1.4 Capacity Production Price Cost Production Value Analysis
5.1.5 Contact Information
5.2 Hisun Pharm
5.2.1 Company Profile
5.2.2 Product Picture and Specification
5.2.3 Product Application Analysis
5.2.4 Capacity Production Price Cost Production Value Analysis
5.2.5 Contact Information
5.3 Company C
5.3.1 Company Profile
5.3.2 Product Picture and Specification
5.3.3 Product Application Analysis
5.3.4 Capacity Production Price Cost Production Value Analysis
5.3.5 Contact Information
CHAPTER SIX ASIA BIOSIMILAR DRUG INDUSTRY DEVELOPMENT TREND
6.1 2017-2021 Biosimilar Drug Capacity Production Trend
6.2 2017-2021 Biosimilar Drug Production Market Share Analysis
6.3 2017-2021 Biosimilar Drug Demand Trend
6.4 2017-2021 Biosimilar Drug Supply Demand and Shortage Analysis
6.5 2017-2021 Biosimilar Drug Import Export Consumption Analysis
6.6 2017-2021 Biosimilar Drug Cost Price Production Value Profit Analysis
PART III NORTH AMERICAN BIOSIMILAR DRUG INDUSTRY (THE REPORT COMPANY INCLUDING THE BELOW LISTED BUT NOT ALL)
CHAPTER SEVEN NORTH AMERICAN BIOSIMILAR DRUG MARKET ANALYSIS
7.1 North American Biosimilar Drug Product Development History
7.2 North American Biosimilar Drug Competitive Landscape Analysis
7.3 North American Biosimilar Drug Market Development Trend
CHAPTER EIGHT 2012-2017 NORTH AMERICAN BIOSIMILAR DRUG PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
8.1 2012-2017 Biosimilar Drug Capacity Production Overview
8.2 2012-2017 Biosimilar Drug Production Market Share Analysis
8.3 2012-2017 Biosimilar Drug Demand Overview
8.4 2012-2017 Biosimilar Drug Supply Demand and Shortage Analysis
8.5 2012-2017 Biosimilar Drug Import Export Consumption Analysis
8.6 2012-2017 Biosimilar Drug Cost Price Production Value Profit Analysis
CHAPTER NINE NORTH AMERICAN BIOSIMILAR DRUG KEY MANUFACTURERS ANALYSIS
9.1 MSD
9.1.1 Company Profile
9.1.2 Product Picture and Specification
9.1.3 Product Application Analysis
9.1.4 Capacity Production Price Cost Production Value Analysis
9.1.5 Contact Information
9.1 Pfizer
9.2.1 Company Profile
9.2.2 Product Picture and Specification
9.2.3 Product Application Analysis
9.2.4 Capacity Production Price Cost Production Value Analysis
9.2.5 Contact Information
CHAPTER TEN NORTH AMERICAN BIOSIMILAR DRUG INDUSTRY DEVELOPMENT TREND
10.1 2017-2021 Biosimilar Drug Capacity Production Trend
10.2 2017-2021 Biosimilar Drug Production Market Share Analysis
10.3 2017-2021 Biosimilar Drug Demand Trend
10.4 2017-2021 Biosimilar Drug Supply Demand and Shortage Analysis
10.5 2017-2021 Biosimilar Drug Import Export Consumption Analysis
10.6 2017-2021 Biosimilar Drug Cost Price Production Value Profit Analysis
PART IV EUROPE BIOSIMILAR DRUG INDUSTRY ANALYSIS (THE REPORT COMPANY INCLUDING THE BELOW LISTED BUT NOT ALL)
CHAPTER ELEVEN EUROPE BIOSIMILAR DRUG MARKET ANALYSIS
11.1 Europe Biosimilar Drug Product Development History
11.2 Europe Biosimilar Drug Competitive Landscape Analysis
11.3 Europe Biosimilar Drug Market Development Trend
CHAPTER TWELVE 2012-2017 EUROPE BIOSIMILAR DRUG PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
12.1 2012-2017 Biosimilar Drug Capacity Production Overview
12.2 2012-2017 Biosimilar Drug Production Market Share Analysis
12.3 2012-2017 Biosimilar Drug Demand Overview
12.4 2012-2017 Biosimilar Drug Supply Demand and Shortage Analysis
12.5 2012-2017 Biosimilar Drug Import Export Consumption Analysis
12.6 2012-2017 Biosimilar Drug Cost Price Production Value Profit Analysis
CHAPTER THIRTEEN EUROPE BIOSIMILAR DRUG KEY MANUFACTURERS ANALYSIS
13.1 Novartis
13.1.1 Company Profile
13.1.2 Product Picture and Specification
13.1.3 Product Application Analysis
13.1.4 Capacity Production Price Cost Production Value Analysis
13.1.5 Contact Information
13.2 Boehringer
13.2.1 Company Profile
13.2.2 Product Picture and Specification
13.2.3 Product Application Analysis
13.2.4 Capacity Production Price Cost Production Value Analysis
13.2.5 Contact Information
CHAPTER FOURTEEN EUROPE BIOSIMILAR DRUG INDUSTRY DEVELOPMENT TREND
14.1 2017-2021 Biosimilar Drug Capacity Production Trend
14.2 2017-2021 Biosimilar Drug Production Market Share Analysis
14.3 2017-2021 Biosimilar Drug Demand Trend
14.4 2017-2021 Biosimilar Drug Supply Demand and Shortage Analysis
14.5 2017-2021 Biosimilar Drug Import Export Consumption Analysis
14.6 2017-2021 Biosimilar Drug Cost Price Production Value Profit Analysis
PART V BIOSIMILAR DRUG MARKETING CHANNELS AND INVESTMENT FEASIBILITY
CHAPTER FIFTEEN BIOSIMILAR DRUG MARKETING CHANNELS DEVELOPMENT PROPOSALS ANALYSIS
15.1 Biosimilar Drug Marketing Channels Status
15.2 Biosimilar Drug Marketing Channels Characteristic
15.3 Biosimilar Drug Marketing Channels Development Trend
15.2 New Firms Enter Market Strategy
15.3 New Project Investment Proposals
CHAPTER SIXTEEN DEVELOPMENT ENVIRONMENTAL ANALYSIS
16.1 China Macroeconomic Environment Analysis
16.2 European Economic Environmental Analysis
16.3 United States Economic Environmental Analysis
16.4 Japan Economic Environmental Analysis
16.5 Global Economic Environmental Analysis
CHAPTER SEVENTEEN BIOSIMILAR DRUG NEW PROJECT INVESTMENT FEASIBILITY ANALYSIS
17.1 Biosimilar Drug Market Analysis
17.2 Biosimilar Drug Project SWOT Analysis
17.3 Biosimilar Drug New Project Investment Feasibility Analysis
PART VI GLOBAL BIOSIMILAR DRUG INDUSTRY CONCLUSIONS
CHAPTER EIGHTEEN 2012-2017 GLOBAL BIOSIMILAR DRUG PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
18.1 2012-2017 Biosimilar Drug Capacity Production Overview
18.2 2012-2017 Biosimilar Drug Production Market Share Analysis
18.3 2012-2017 Biosimilar Drug Demand Overview
18.4 2012-2017 Biosimilar Drug Supply Demand and Shortage Analysis
18.5 2012-2017 Biosimilar Drug Cost Price Production Value Profit Analysis
CHAPTER NINETEEN GLOBAL BIOSIMILAR DRUG INDUSTRY DEVELOPMENT TREND
19.1 2017-2021 Biosimilar Drug Capacity Production Trend
19.2 2017-2021 Biosimilar Drug Production Market Share Analysis
19.3 2017-2021 Biosimilar Drug Demand Trend
19.4 2017-2021 Biosimilar Drug Supply Demand and Shortage Analysis
19.5 2017-2021 Biosimilar Drug Cost Price Production Value Profit Analysis
CHAPTER TWENTY GLOBAL BIOSIMILAR DRUG INDUSTRY RESEARCH CONCLUSIONS
CHAPTER ONE BIOSIMILAR DRUG INDUSTRY OVERVIEW
1.1 Biosimilar Drug Definition
1.2 Biosimilar Drug Classification Analysis
mAbs (Monoclonal Antibodies)
FC-Fusion Proteins
EPO (Erythropoietin)
1.2.1 Biosimilar Drug Main Classification Analysis
1.2.2 Biosimilar Drug Main Classification Share Analysis
1.3 Biosimilar Drug Application Analysis
Oncology
Diabetes
Rheumatoid arthritis
1.3.1 Biosimilar Drug Main Application Analysis
1.3.2 Biosimilar Drug Main Application Share Analysis
1.4 Biosimilar Drug Industry Chain Structure Analysis
1.5 Biosimilar Drug Industry Development Overview
1.5.1 Biosimilar Drug Product History Development Overview
1.5.1 Biosimilar Drug Product Market Development Overview
1.6 Biosimilar Drug Global Market Comparison Analysis
1.6.1 Biosimilar Drug Global Import Market Analysis
1.6.2 Biosimilar Drug Global Export Market Analysis
1.6.3 Biosimilar Drug Global Main Region Market Analysis
1.6.4 Biosimilar Drug Global Market Comparison Analysis
1.6.5 Biosimilar Drug Global Market Development Trend Analysis
CHAPTER TWO BIOSIMILAR DRUG UP AND DOWN STREAM INDUSTRY ANALYSIS
2.1 Upstream Raw Materials Analysis
2.1.1 Upstream Raw Materials Price Analysis
2.1.2 Upstream Raw Materials Market Analysis
2.1.3 Upstream Raw Materials Market Trend
2.2 Down Stream Market Analysis
2.1.1 Down Stream Market Analysis
2.2.2 Down Stream Demand Analysis
2.2.3 Down Stream Market Trend Analysis
PART II ASIA BIOSIMILAR DRUG INDUSTRY (THE REPORT COMPANY INCLUDING THE BELOW LISTED BUT NOT ALL)
CHAPTER THREE ASIA BIOSIMILAR DRUG MARKET ANALYSIS
3.1 Asia Biosimilar Drug Product Development History
3.2 Asia Biosimilar Drug Competitive Landscape Analysis
3.3 Asia Biosimilar Drug Market Development Trend
CHAPTER FOUR 2012-2017 ASIA BIOSIMILAR DRUG PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
4.1 2012-2017 Biosimilar Drug Capacity Production Overview
4.2 2012-2017 Biosimilar Drug Production Market Share Analysis
4.3 2012-2017 Biosimilar Drug Demand Overview
4.4 2012-2017 Biosimilar Drug Supply Demand and Shortage Analysis
4.5 2012-2017 Biosimilar Drug Import Export Consumption Analysis
4.6 2012-2017 Biosimilar Drug Cost Price Production Value Profit Analysis
CHAPTER FIVE ASIA BIOSIMILAR DRUG KEY MANUFACTURERS ANALYSIS
5.1 Hengrui Medicine
5.1.1 Company Profile
5.1.2 Product Picture and Specification
5.1.3 Product Application Analysis
5.1.4 Capacity Production Price Cost Production Value Analysis
5.1.5 Contact Information
5.2 Hisun Pharm
5.2.1 Company Profile
5.2.2 Product Picture and Specification
5.2.3 Product Application Analysis
5.2.4 Capacity Production Price Cost Production Value Analysis
5.2.5 Contact Information
5.3 Company C
5.3.1 Company Profile
5.3.2 Product Picture and Specification
5.3.3 Product Application Analysis
5.3.4 Capacity Production Price Cost Production Value Analysis
5.3.5 Contact Information
CHAPTER SIX ASIA BIOSIMILAR DRUG INDUSTRY DEVELOPMENT TREND
6.1 2017-2021 Biosimilar Drug Capacity Production Trend
6.2 2017-2021 Biosimilar Drug Production Market Share Analysis
6.3 2017-2021 Biosimilar Drug Demand Trend
6.4 2017-2021 Biosimilar Drug Supply Demand and Shortage Analysis
6.5 2017-2021 Biosimilar Drug Import Export Consumption Analysis
6.6 2017-2021 Biosimilar Drug Cost Price Production Value Profit Analysis
PART III NORTH AMERICAN BIOSIMILAR DRUG INDUSTRY (THE REPORT COMPANY INCLUDING THE BELOW LISTED BUT NOT ALL)
CHAPTER SEVEN NORTH AMERICAN BIOSIMILAR DRUG MARKET ANALYSIS
7.1 North American Biosimilar Drug Product Development History
7.2 North American Biosimilar Drug Competitive Landscape Analysis
7.3 North American Biosimilar Drug Market Development Trend
CHAPTER EIGHT 2012-2017 NORTH AMERICAN BIOSIMILAR DRUG PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
8.1 2012-2017 Biosimilar Drug Capacity Production Overview
8.2 2012-2017 Biosimilar Drug Production Market Share Analysis
8.3 2012-2017 Biosimilar Drug Demand Overview
8.4 2012-2017 Biosimilar Drug Supply Demand and Shortage Analysis
8.5 2012-2017 Biosimilar Drug Import Export Consumption Analysis
8.6 2012-2017 Biosimilar Drug Cost Price Production Value Profit Analysis
CHAPTER NINE NORTH AMERICAN BIOSIMILAR DRUG KEY MANUFACTURERS ANALYSIS
9.1 MSD
9.1.1 Company Profile
9.1.2 Product Picture and Specification
9.1.3 Product Application Analysis
9.1.4 Capacity Production Price Cost Production Value Analysis
9.1.5 Contact Information
9.1 Pfizer
9.2.1 Company Profile
9.2.2 Product Picture and Specification
9.2.3 Product Application Analysis
9.2.4 Capacity Production Price Cost Production Value Analysis
9.2.5 Contact Information
CHAPTER TEN NORTH AMERICAN BIOSIMILAR DRUG INDUSTRY DEVELOPMENT TREND
10.1 2017-2021 Biosimilar Drug Capacity Production Trend
10.2 2017-2021 Biosimilar Drug Production Market Share Analysis
10.3 2017-2021 Biosimilar Drug Demand Trend
10.4 2017-2021 Biosimilar Drug Supply Demand and Shortage Analysis
10.5 2017-2021 Biosimilar Drug Import Export Consumption Analysis
10.6 2017-2021 Biosimilar Drug Cost Price Production Value Profit Analysis
PART IV EUROPE BIOSIMILAR DRUG INDUSTRY ANALYSIS (THE REPORT COMPANY INCLUDING THE BELOW LISTED BUT NOT ALL)
CHAPTER ELEVEN EUROPE BIOSIMILAR DRUG MARKET ANALYSIS
11.1 Europe Biosimilar Drug Product Development History
11.2 Europe Biosimilar Drug Competitive Landscape Analysis
11.3 Europe Biosimilar Drug Market Development Trend
CHAPTER TWELVE 2012-2017 EUROPE BIOSIMILAR DRUG PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
12.1 2012-2017 Biosimilar Drug Capacity Production Overview
12.2 2012-2017 Biosimilar Drug Production Market Share Analysis
12.3 2012-2017 Biosimilar Drug Demand Overview
12.4 2012-2017 Biosimilar Drug Supply Demand and Shortage Analysis
12.5 2012-2017 Biosimilar Drug Import Export Consumption Analysis
12.6 2012-2017 Biosimilar Drug Cost Price Production Value Profit Analysis
CHAPTER THIRTEEN EUROPE BIOSIMILAR DRUG KEY MANUFACTURERS ANALYSIS
13.1 Novartis
13.1.1 Company Profile
13.1.2 Product Picture and Specification
13.1.3 Product Application Analysis
13.1.4 Capacity Production Price Cost Production Value Analysis
13.1.5 Contact Information
13.2 Boehringer
13.2.1 Company Profile
13.2.2 Product Picture and Specification
13.2.3 Product Application Analysis
13.2.4 Capacity Production Price Cost Production Value Analysis
13.2.5 Contact Information
CHAPTER FOURTEEN EUROPE BIOSIMILAR DRUG INDUSTRY DEVELOPMENT TREND
14.1 2017-2021 Biosimilar Drug Capacity Production Trend
14.2 2017-2021 Biosimilar Drug Production Market Share Analysis
14.3 2017-2021 Biosimilar Drug Demand Trend
14.4 2017-2021 Biosimilar Drug Supply Demand and Shortage Analysis
14.5 2017-2021 Biosimilar Drug Import Export Consumption Analysis
14.6 2017-2021 Biosimilar Drug Cost Price Production Value Profit Analysis
PART V BIOSIMILAR DRUG MARKETING CHANNELS AND INVESTMENT FEASIBILITY
CHAPTER FIFTEEN BIOSIMILAR DRUG MARKETING CHANNELS DEVELOPMENT PROPOSALS ANALYSIS
15.1 Biosimilar Drug Marketing Channels Status
15.2 Biosimilar Drug Marketing Channels Characteristic
15.3 Biosimilar Drug Marketing Channels Development Trend
15.2 New Firms Enter Market Strategy
15.3 New Project Investment Proposals
CHAPTER SIXTEEN DEVELOPMENT ENVIRONMENTAL ANALYSIS
16.1 China Macroeconomic Environment Analysis
16.2 European Economic Environmental Analysis
16.3 United States Economic Environmental Analysis
16.4 Japan Economic Environmental Analysis
16.5 Global Economic Environmental Analysis
CHAPTER SEVENTEEN BIOSIMILAR DRUG NEW PROJECT INVESTMENT FEASIBILITY ANALYSIS
17.1 Biosimilar Drug Market Analysis
17.2 Biosimilar Drug Project SWOT Analysis
17.3 Biosimilar Drug New Project Investment Feasibility Analysis
PART VI GLOBAL BIOSIMILAR DRUG INDUSTRY CONCLUSIONS
CHAPTER EIGHTEEN 2012-2017 GLOBAL BIOSIMILAR DRUG PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
18.1 2012-2017 Biosimilar Drug Capacity Production Overview
18.2 2012-2017 Biosimilar Drug Production Market Share Analysis
18.3 2012-2017 Biosimilar Drug Demand Overview
18.4 2012-2017 Biosimilar Drug Supply Demand and Shortage Analysis
18.5 2012-2017 Biosimilar Drug Cost Price Production Value Profit Analysis
CHAPTER NINETEEN GLOBAL BIOSIMILAR DRUG INDUSTRY DEVELOPMENT TREND
19.1 2017-2021 Biosimilar Drug Capacity Production Trend
19.2 2017-2021 Biosimilar Drug Production Market Share Analysis
19.3 2017-2021 Biosimilar Drug Demand Trend
19.4 2017-2021 Biosimilar Drug Supply Demand and Shortage Analysis
19.5 2017-2021 Biosimilar Drug Cost Price Production Value Profit Analysis
CHAPTER TWENTY GLOBAL BIOSIMILAR DRUG INDUSTRY RESEARCH CONCLUSIONS
